Matinas Biopharma Holdings, Inc. (NYSE:MTNB – Get Free Report) was down 6.6% during mid-day trading on Tuesday . The stock traded as low as $0.53 and last traded at $0.56. Approximately 46,870 shares changed hands during mid-day trading, a decline of 74% from the average daily volume of 182,658 shares. The stock had previously closed at $0.60.
Matinas Biopharma Stock Performance
The company has a market cap of $2.87 million, a price-to-earnings ratio of -0.12 and a beta of 1.54. The business’s 50-day moving average is $0.58.
Matinas Biopharma Company Profile
Matinas BioPharma Holdings, Inc is a clinical-stage biopharmaceutical company. It engages in the business of delivering groundbreaking therapies using lipid nanocrystal platform delivery technology to maximize global clinical impact and patient access. The company was founded by Herbert J. Conrad and Jerome D.
See Also
- Five stocks we like better than Matinas Biopharma
- Market Cap Calculator: How to Calculate Market Cap
- Penny Stock SurgePays Rises 70%: 1 Reason to Buy, 5 to Sell
- How to Capture the Benefits of Dividend Increases
- Top 3 Beverage Stocks Pouring Out Profits
- How to Use Stock Screeners to Find Stocks
- CarMax and Carvana: Steering the Used Car Market
Receive News & Ratings for Matinas Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Matinas Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
